Skip to main content

Table 2 Clinical findings and documented indications at tocolysis cycle 1, 2, and 3

From: Differences between evidence-based recommendations and actual clinical practice regarding tocolysis: a prospective multicenter registry study

Tocolysis cycle

Total

1st

2nd

3rd

Patients (n)

309/509 cycles

309

129

47

Clinical findings

 Preterm labor

280 (55.0%)

148 (47.9%)

83 (64.3%)

32 (68.1%)

 Isolated CXI

146 (28.7%)

98 (31.7%)

92 (71.3%)

37 (78.7%)

 PROM

38 (7.5%)

29 (9.4%)

5 (3.9%)

2 (4.3%)

 Genital Infection

20 (3.9%)

13 (4.2%)

4 (3.1%)

3 (6.4%)

 CX < 25 mm

379 (74.5%)

227 (73.5%)

103 (79.8%)

30 (63.8%)

 Cervical length

34.6 ± 51.9

36.06 ± 56.0

33.41 ± 48.2

31.43 ± 42.21

 Multiple prenancy

148 (29.1%)

78 (25.2%)

42 (32.6%)

21 (44.7%)

Indication for tocolysis

 Lung maturation

289 (56.8%)

234 (75.7%)

40 (31.0%)

8 (17.0%)

 Prolongation of pregnancy

218 (42.8%)

73 (23.6%)

89 (69.0%)

39 (83.0%)

 Transfer to center

2 (0.4%)

2 (0.7%)

0 (0.0%)

0 (0.0%)

GA at beginning (weeks)

28.32 ± 3.3

27.68 ± 3.5

29.09 ± 2.9

29.32 ± 2.7

Duration of tocolysis (days)

4.8 ± 6.3

4.78 ± 6.8

4.61 ± 5.7

4.63 ± 4.7

Type

Atosiban

439 (86.2%)

263 (85.1%)

115 (89.1%)

39 (83.0%)

Hexoprenaline

43 (8.5%)

30 (9.7%)

8 (6.2%)

5 (10.6%)

Nifedipine

2 (0.4%)

0 (0.0%)

1 (0.8%)

0 (0.0%)

Switch of substance/double medication

25 (4.9%)

16 (5.2%)

5 (3.9%)

3 (6.4%)

  1. CXI cervical insufficiency, PROM preterm rupture of membranes, CX cervical length, GA gestational age